|
|
|
Volumn 269, Issue 7221, 2002, Pages 599-600
|
|
Pharmageddon: Is it too late to tackle growing resistance to anti-infectives?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMOXICILLIN PLUS CLAVULANIC ACID;
ANTIBIOTIC AGENT;
ANTIFUNGAL AGENT;
ANTIINFECTIVE AGENT;
ANTIVIRUS AGENT;
BIOCIDE;
DALFOPRISTIN PLUS QUINUPRISTIN;
DAPTOMYCIN;
LINEZOLID;
ORITAVANCIN;
OXAZOLIDINONE DERIVATIVE;
TETRACYCLINE DERIVATIVE;
TIGECYCLINE;
TRICLOSAN;
UNCLASSIFIED DRUG;
ANTIBIOTIC RESISTANCE;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSS REACTION;
DRUG INDUSTRY;
DRUG UTILIZATION;
GENOMICS;
GRAM NEGATIVE BACTERIUM;
GRAM POSITIVE BACTERIUM;
HUMAN;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
MULTIDRUG RESISTANCE;
NONHUMAN;
NOTE;
PATIENT COMPLIANCE;
PHARMACIST;
PRESCRIPTION;
|
|
EID: 0037180130
PISSN: 00316873
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (15)
|
|
References (0)
|